Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

ABSTRACT:

Background

Chondrosarcoma is a heterogeneous group of primary bone sarcoma with an excellent overall survival after local therapy. However, the small percentage of patients who have no surgical treatment options have a very poor prognosis. We retrospectively collected data from these patients in four sarcoma centers and compared the progression-free survival (PFS) for the different treatment regimens used for the four chondrosarcoma subtypes.

Materials and methods

Patients diagnosed with unresectable chondrosarcoma in all four major sarcoma centers were included, and data on first-line systemic therapy were retrospectively collected for analysis.

Results

A total of 112 patients were enrolled in this retrospective analysis: 50 conventional, 25 mesenchymal, 34 dediffere

SUBMITTER: van Maldegem A 

PROVIDER: S-EPMC6324625 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature